Shares of Urovant Sciences Ltd (NASDAQ:UROV) have been assigned a consensus rating of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $24.00.
Several analysts have recently weighed in on UROV shares. JPMorgan Chase & Co. set a $24.00 target price on Urovant Sciences and gave the company a “buy” rating in a research note on Friday, June 14th. HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of Urovant Sciences in a research report on Monday. Zacks Investment Research cut Urovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. Finally, ValuEngine raised Urovant Sciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Shares of UROV stock traded down $1.22 on Friday, hitting $9.13. The stock had a trading volume of 113,441 shares, compared to its average volume of 53,514. The stock’s 50 day moving average is $8.39 and its 200-day moving average is $9.00. The firm has a market capitalization of $277.00 million and a price-to-earnings ratio of -2.06. Urovant Sciences has a 52-week low of $4.05 and a 52-week high of $14.49. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.20 and a current ratio of 6.20.
In related news, major shareholder Andrew Lo bought 18,204 shares of the business’s stock in a transaction dated Wednesday, June 19th. The shares were acquired at an average price of $8.32 per share, for a total transaction of $151,457.28. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Holdings Ltd. Dexxon purchased 22,011 shares of Urovant Sciences stock in a transaction dated Friday, June 14th. The shares were bought at an average cost of $8.06 per share, for a total transaction of $177,408.66. The disclosure for this purchase can be found here. 2.40% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC increased its holdings in Urovant Sciences by 116.7% in the second quarter. Perceptive Advisors LLC now owns 1,875,426 shares of the company’s stock valued at $14,835,000 after buying an additional 1,010,067 shares during the last quarter. FMR LLC raised its stake in Urovant Sciences by 28.4% during the first quarter. FMR LLC now owns 1,710,836 shares of the company’s stock valued at $17,194,000 after buying an additional 378,135 shares in the last quarter. Atria Investments LLC acquired a new stake in Urovant Sciences during the second quarter valued at approximately $3,420,000. Marshall Wace LLP bought a new position in Urovant Sciences during the 1st quarter worth approximately $325,000. Finally, Vanguard Group Inc. lifted its holdings in Urovant Sciences by 7.3% during the 2nd quarter. Vanguard Group Inc. now owns 131,487 shares of the company’s stock worth $1,040,000 after buying an additional 9,000 shares during the last quarter. Institutional investors and hedge funds own 24.10% of the company’s stock.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Featured Article: Gap Up Stocks
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.